When LIRA QD was compared to placebo injections in T2DM patients taking MET+ROSI for a period of 26 weeks, HOMA-B improved from a baseline of 34%-37% to 61%-64% (P<0.0001), whereas the mean ratio of proinsulin-to-insulin versus placebo decreased significantly (P<0.05) [115]. The gene discussed is INS; the disease is type 2 diabetes mellitus.